surface plasmon resonance biacore 2000 apparatus (Biacore)
90
Structured Review
Biacore
surface plasmon resonance biacore 2000 apparatus
Surface Plasmon Resonance Biacore 2000 Apparatus, supplied by Biacore, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/surface+plasmon+resonance+biacore+2000+apparatus/biacore+3000+instrument/pm25504081-239-12-15
Average 90 stars, based on 1 article reviews
Surface Plasmon Resonance Biacore 2000 Apparatus, supplied by Biacore, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/surface+plasmon+resonance+biacore+2000+apparatus/biacore+3000+instrument/pm25504081-239-12-15
Average 90 stars, based on 1 article reviews
surface plasmon resonance biacore 2000 apparatus - by Bioz Stars,
2026-11
90/100 stars
Images
Related Articles
Binding Assay:Article Title: Targeting FR-expressing cells in ovarian cancer with Fab-functionalized nanoparticles: a full study to provide the proof of principle from in vitro to in vivo. Article Snippet: Efficient targeting in tumor therapies is still an open issue: systemic biodistribution and poor specific accumulation of drugs weaken efficacy of treatments.. Engineered nanoparticles are expected to bring benefits by allowing specific delivery of drug to the tumor or acting themselves as localized therapeutic agents.. In this study we have targeted epithelial ovarian cancer with inorganic nanoparticles conjugated to a human antibody fragment against the folate receptor over-expressed on cancer cells. SPR Assay:Article Title: Targeting FR-expressing cells in ovarian cancer with Fab-functionalized nanoparticles: a full study to provide the proof of principle from in vitro to in vivo. Article Snippet: Efficient targeting in tumor therapies is still an open issue: systemic biodistribution and poor specific accumulation of drugs weaken efficacy of treatments.. Engineered nanoparticles are expected to bring benefits by allowing specific delivery of drug to the tumor or acting themselves as localized therapeutic agents.. In this study we have targeted epithelial ovarian cancer with inorganic nanoparticles conjugated to a human antibody fragment against the folate receptor over-expressed on cancer cells. |